MEDICAL LETTER ON DRUGS AND THERAPEUTICS

Scope & Guideline

Decoding Drug Innovations for Healthcare Professionals

Introduction

Welcome to the MEDICAL LETTER ON DRUGS AND THERAPEUTICS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of MEDICAL LETTER ON DRUGS AND THERAPEUTICS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0025-732x
PublisherMED LETTER INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1965 to 2024
AbbreviationMED LETT DRUGS THER / Med. Lett. Drugs Ther.
Frequency26 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address145 HUGUENOT ST, SUITE 312, NEW ROCHELLE, NY 10801-7537

Aims and Scopes

The journal "Medical Letter on Drugs and Therapeutics" focuses on providing concise, evidence-based information about medications and their therapeutic uses. Its primary aim is to assist healthcare professionals in making informed decisions regarding drug therapy.
  1. Drug Evaluation and Comparison:
    The journal evaluates new drugs, comparing them to existing therapies, and highlighting their efficacy, safety, and cost-effectiveness.
  2. Updates on Therapeutics:
    It provides ongoing updates regarding new therapeutic indications, formulations, and clinical guidelines for various drug classes.
  3. Public Health and Vaccination:
    The journal emphasizes public health initiatives, particularly in vaccination strategies, and the management of infectious diseases.
  4. Clinical Guidelines and Recommendations:
    It offers practical clinical guidelines and recommendations based on the latest evidence and consensus in the field of pharmacotherapy.
  5. Continuing Medical Education (CME):
    The journal incorporates CME components to ensure healthcare professionals remain updated on the latest developments in drug therapy.
The journal has identified several emerging themes in drug therapy that reflect current healthcare challenges and advancements in pharmacotherapy. These themes are increasingly relevant to clinicians and researchers alike.
  1. Vaccination and Preventative Therapies:
    There is a growing emphasis on vaccination, particularly in light of the COVID-19 pandemic, with numerous articles focusing on new vaccine formulations and their therapeutic applications.
  2. Gene and Cell Therapies:
    The journal is increasingly covering innovative gene and cell therapies, highlighting breakthroughs in the treatment of genetic disorders and certain cancers.
  3. Biologics and Targeted Therapies:
    A significant trend towards biologics and targeted therapies in various fields, including oncology and immunology, indicates a shift in treatment paradigms.
  4. Mental Health and Depression Treatments:
    With rising mental health concerns, there is an increasing number of articles focused on new treatment options for depression and anxiety disorders.
  5. Digital Health and Telemedicine:
    The integration of digital health technologies and telemedicine in drug therapy has emerged as a relevant topic, reflecting the changes in healthcare delivery models.

Declining or Waning

In recent years, certain therapeutic areas and topics have seen a decline in coverage within the journal. This shift may reflect changes in clinical focus or advancements in therapeutic options.
  1. Long-term Chronic Disease Management:
    There has been a noticeable decline in articles focused on chronic disease management strategies, possibly due to the increasing emphasis on novel therapies and acute interventions.
  2. Traditional Antibiotics:
    Coverage of traditional antibiotics has waned, likely due to the rise of resistance issues and the introduction of novel agents that overshadow older drugs.
  3. Over-the-Counter (OTC) Medications:
    The frequency of articles discussing OTC medications has decreased, which may indicate a shift towards prescription-only therapies as primary treatment options.
  4. Pain Management with Opioids:
    As the opioid crisis continues, there has been a reduction in articles focusing on opioid therapies, reflecting a broader trend toward non-opioid pain management.
  5. Psychiatric Drug Treatments:
    The journal has seen a decrease in the number of articles specifically addressing traditional psychiatric medications, possibly due to a shift toward newer treatment modalities and therapies.

Similar Journals

CLINICAL PHARMACOLOGY & THERAPEUTICS

Leading the way in pharmacology and therapeutics excellence.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Annales Pharmaceutiques Francaises

Fostering Excellence in Pharmaceutical Research and Development
Publisher: MASSON EDITEURISSN: 0003-4509Frequency: 6 issues/year

Annales Pharmaceutiques Francaises, an esteemed journal published by MASSON EDITEUR, serves as a pivotal platform in the field of Pharmaceutical Science and Pharmacology. Established in 1945 and continuing through 2024, this journal showcases significant contributions to the advancement of pharmaceutical sciences, bridging the gap between research, development, and practical applications. Although it currently does not offer open access, its established reputation and Q3 ranking in both Pharmaceutical Science and Pharmacology highlight its role in disseminating impactful studies. With an ISSN of 0003-4509, the journal is indexed in Scopus, boasting a respectable percentile ranking for both domains, and remains a vital resource for researchers, professionals, and students dedicated to exploring the latest advancements in the pharmaceutical field. Based in France, at 21 Street Camille Desmoulins, Issy, 92789 Moulinais Cedex 9, it aims to foster a deeper understanding of pharmacological innovations and therapeutic agents among its diverse readership.

TRENDS IN PHARMACOLOGICAL SCIENCES

Navigating Innovations in Pharmacology and Toxicology
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

Journal of Taibah University Medical Sciences

Exploring the Frontiers of Medical Science Together
Publisher: ELSEVIERISSN: 1658-3612Frequency: 6 issues/year

Welcome to the Journal of Taibah University Medical Sciences, a distinguished open-access publication dedicated to advancing knowledge in the field of medicine. Since its inception in 2006, and published by ELSEVIER, this journal has become a vital resource for researchers and healthcare professionals alike, reflecting a steadfast commitment to disseminating innovative research and high-quality medical studies. With an impressive impact factor and a Scopus ranking placing it in the top 25% of general medicine journals, this publication occupies a notable position in the academic landscape. The journal covers a wide array of topics within the medical sciences, from clinical research to public health initiatives. As a Q3 category journal in the 2023 rankings, it continues to attract submissions that contribute meaningfully to the diverse and evolving field of medicine, supporting an open-access model that ensures widespread accessibility to its invaluable content. Explore the Journal of Taibah University Medical Sciences to stay abreast of the latest scientific advancements and engage with fellow scholars across the globe.

New Armenian Medical Journal

Advancing Medical Knowledge, One Article at a Time.
Publisher: YEREVAN STATE MEDICAL UNIVISSN: 1829-0825Frequency: 4 issues/year

New Armenian Medical Journal (ISSN: 1829-0825, E-ISSN: 1829-0825) is a prominent academic publication established by Yerevan State Medical University, dedicated to advancing the field of medicine through high-quality research and scholarly discourse. Located in Armenia, this journal serves as a vital platform for disseminating innovative findings and clinical practices, with a particular focus on the regional healthcare landscape as well as global health issues. While currently categorized in the lower quartile (Q4) of general medicine, it demonstrates a commitment to improving its impact factor and ranking, evidenced by its ongoing publication from 2009 to 2024. The journal embraces a diverse scope that encompasses miscellaneous topics within medical research, catering to the needs of practitioners, researchers, and students alike. Though not an open-access journal, it offers valuable insights and knowledge that contribute meaningfully to the medical community. By participating in this scholarly dialogue, readers can enhance their understanding and foster advancements in the ever-evolving field of medicine.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Connecting researchers and practitioners in pharmacology.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

DRUGS

Shaping the Future of Pharmaceutical Science
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

JOURNAL OF AVIAN MEDICINE AND SURGERY

Empowering professionals in avian health and surgical excellence.
Publisher: ASSOC AVIAN VETERINARIANSISSN: 1082-6742Frequency: 4 issues/year

JOURNAL OF AVIAN MEDICINE AND SURGERY, published by the Association of Avian Veterinarians, serves as an essential resource for professionals and researchers in the field of avian veterinary medicine. Established in 1996, the journal has consistently contributed to the understanding and advancement of medical and surgical practices in avian species, showcasing innovative research and comprehensive reviews that address the unique health challenges faced by birds. With an ISSN of 1082-6742 and an E-ISSN of 1938-2871, this journal is indexed in Scopus, ranking 13th out of 20 in the Small Animals category, placing it within the 37th percentile and exemplifying its impact in the veterinary community. Although not an Open Access journal, it is vital for advancing knowledge and improving veterinary care for avian clients. Its commitment to excellence is reflected in its designation within the Q3 quartile in both miscellaneous medicine and small animals, indicating its growing influence and relevance in the veterinary literature. The journal encourages contributions that enhance the understanding of avian health, providing a platform for ideas that will drive progress in this niche field.

Drug Healthcare and Patient Safety

Fostering global discourse on drug healthcare advancements.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1365Frequency: 1 issue/year

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.